Sanches et al. (2016) demonstrated that mice immunized with an anti-bevacizumab idiotype mAb have reduced B16-F10 tumor growth, with more extensive necrotic areas, reduced CD31-positive vascular density, and decreased infiltration of CD68-positive cells (Sanches et al., 2016). This evidence concerns the gene CD68 and neoplasm.